Literature DB >> 21486111

Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes.

Alev E Altinova1, Fusun Toruner, Mujde Akturk, Neslihan Bukan, Ilhan Yetkin, Nuri Cakir, Metin Arslan.   

Abstract

We aimed to investigate the relationship between serum osteoprotegerin (OPG) level and glycemic control, lipids, renal function, microalbuminuria, insulin resistance and markers of atherosclerosis including C-reactive protein (CRP), fibrinogen and erythrocyte sedimentation rate (ESR) in patients with type 2 diabetes mellitus (DM). A total of 166 patients (99 women and 67 men) with type 2 DM were recruited in the study. Serum OPG level was higher in poorly controlled diabetic patients (HbA(1c) ≥ 7%) than in well-controlled diabetic patients (HbA(1c) < 7%) [4.0 (3.6-5.0) and 3.5 (2.9-4.4) pmol/L, p = 0.02]. There was no difference between the patients with and without microalbuminuria with respect to OPG levels (p > 0.05). LogOPG was correlated with age (r = 0.47, p = 0.0001). After adjustment for age, sex and BMI, logOPG correlated positively with fasting blood glucose (FBG) (r = 0.28, p = 0.001), prandial blood glucose (PBG) (r = 0.22, p = 0.009), glycated hemoglobin (HbA(1c)) (r = 0.26, p = 0.002), logHOMA-IR (r = 0.30, p = 0.006), fibrinogen (r = 0.17, p = 0.04), mean albumin excretion rate (MAER) (r = 0.20, p = 0.01) and negatively with creatinine clearance (r = - 0.20, p = 0.01). Regression analysis revealed that logOPG was independently associated with age (p = 0.0001), HbA(1c) (p = 0.01) and MAER (p = 0.02) (r(2) = 0.25). In conclusion; we found that serum OPG levels are increased in poorly controlled type 2 DM and associated with age, glycemic control and microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486111     DOI: 10.3109/00365513.2011.570868

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  10 in total

1.  Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.

Authors:  Raelene E Maser; M James Lenhard; Michael B Sneider; Ryan T Pohlig
Journal:  Endocr Pract       Date:  2015-01       Impact factor: 3.443

2.  Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus.

Authors:  Mikael K Poulsen; Mads Nybo; Jordi Dahl; Susanne Hosbond; Tina S Poulsen; Allan Johansen; Poul F Høilund-Carlsen; Henning Beck-Nielsen; Lars M Rasmussen; Jan E Henriksen
Journal:  Cardiovasc Diabetol       Date:  2011-08-12       Impact factor: 9.951

Review 3.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

4.  Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study.

Authors:  Yixin Niu; Zhen Yang; Xiaoyong Li; Weiwei Zhang; Shuai Lu; Hongmei Zhang; Xueru Chen; Lingfei Zhu; Yin Xing; Guang Ning; Li Qin; Qing Su
Journal:  BMC Endocr Disord       Date:  2015-12-01       Impact factor: 2.763

5.  Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes.

Authors:  Peng Duan; Min Yang; Meilin Wei; Jia Liu; Ping Tu
Journal:  Int J Endocrinol       Date:  2017-01-31       Impact factor: 3.257

6.  Smoking and other determinants of bone turnover.

Authors:  Rolf Jorde; Astrid Kamilla Stunes; Julia Kubiak; Guri Grimnes; Per Medbøe Thorsby; Unni Syversen
Journal:  PLoS One       Date:  2019-11-25       Impact factor: 3.240

7.  Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).

Authors:  Tae Ryom Oh; Chana Myeong; Su Hyun Song; Hong Sang Choi; Sang Heon Suh; Chang Seong Kim; Eun Hui Bae; Wookyung Chung; Kyu Hun Choi; Kook Hwan Oh; Seong Kwon Ma; Soo Wan Kim
Journal:  Kidney Res Clin Pract       Date:  2021-12-29

8.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

Review 9.  BONE MARKERS IN ARTHROPATHIES.

Authors:  Roxana Răduț; Alexandra M Crăciun; Ciprian N Silaghi
Journal:  Acta Clin Croat       Date:  2019-12       Impact factor: 0.932

10.  Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants.

Authors:  Lena Tschiderer; Gerhard Klingenschmid; Rajini Nagrani; Johann Willeit; Jari A Laukkanen; Georg Schett; Stefan Kiechl; Peter Willeit
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.